About: Reassessing therapeutic antibodies for neglected and tropical diseases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Reassessing therapeutic antibodies for neglected and tropical diseases Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Reassessing therapeutic antibodies for neglected and tropical diseases
Creator	Akahata, Wataru Katsuno, Kei Kojima, Somei Okabe, Hisafumi Sato, Akihide Wells, Timothy Carterid, Dee Hooft Van Huijsduijnen, Rob
Source	PMC
abstract	In the past two decades there has been a significant expansion in the number of new therapeutic monoclonal antibodies (mAbs) that are approved by regulators. The discovery of these new medicines has been driven primarily by new approaches in inflammatory diseases and oncology, especially in immuno-oncology. Other recent successes have included new antibodies for use in viral diseases, including HIV. The perception of very high costs associated with mAbs has led to the assumption that they play no role in prophylaxis for diseases of poverty. However, improvements in antibody-expression yields and manufacturing processes indicate this is a cost-effective option for providing protection from many types of infection that should be revisited. Recent technology developments also indicate that several months of protection could be achieved with a single dose. Moreover, new methods in B cell sorting now enable the systematic identification of high-quality antibodies from humanized mice, or patients. This Review discusses the potential for passive immunization against schistosomiasis, fungal infections, dengue, and other neglected diseases.
has issue date	2020-01-30(xsd:dateTime)
bibo:doi	10.1371/journal.pntd.0007860
bibo:pmid	31999695
has license	cc-by
sha1sum (hex)	38c9ad4d6eb48945732f8519c795b39b4bdb0c93
schema:url	https://doi.org/10.1371/journal.pntd.0007860
resource representing a document's title	Reassessing therapeutic antibodies for neglected and tropical diseases
has PubMed Central identifier	PMC6991954
has PubMed identifier	31999695
schema:publication	PLoS Negl Trop Dis
resource representing a document's body	covid:38c9ad4d6eb48945732f8519c795b39b4bdb0c93#body_text
is schema:about of	named entity 'NEGLECTED' named entity 'APPROVED BY' named entity 'THERAPEUTIC' named entity 'POTENTIAL' named entity 'DISCOVERY' named entity 'OPTION' named entity 'MONOCLONAL ANTIBODIES' named entity 'QUALITY' named entity 'MANUFACTURING PROCESSES' named entity 'COSTS' named entity 'IN THE PAST' named entity 'DRIVEN' named entity 'ANTIBODY' named entity 'PATIENTS' named entity 'HAVE' named entity 'DISEASES' named entity 'REVIEW' named entity 'LED' named entity 'B CELL' named entity 'EXPANSION' named entity 'HIV' named entity 'SUCCESSES' named entity 'ENABLE' named entity 'INCLUDING' named entity 'IS A' named entity 'NUMBER OF' named entity 'EXPRESSION' named entity 'ROLE' named entity 'REGULATORS' named entity 'TECHNOLOGY' named entity 'PERCEPTION' named entity 'INFECTION' named entity 'PROTECTION' named entity 'THESE' named entity 'NEW' named entity 'MONTHS' named entity 'VERY HIGH' named entity 'APPROACHES' named entity 'MEDICINES' named entity 'VIRAL DISEASES' named entity 'PROPHYLAXIS' named entity 'SCHISTOSOMIASIS' named entity 'THERAPEUTIC ANTIBODIES' named entity 'TROPICAL DISEASES' named entity 'PLAY' named entity 'USE' named entity 'FUNGAL INFECTIONS' named entity 'COST' named entity 'METHODS' named entity 'ANTIBODIES' named entity 'EFFECTIVE' named entity 'IDENTIFICATION' named entity 'SINGLE' named entity 'PROVIDING' named entity 'TYPES' named entity 'HUMANIZED MICE' named entity 'CELL SORTING' named entity 'INFLAMMATORY DISEASES' named entity 'DEVELOPMENTS' named entity 'POVERTY' named entity 'INCLUDED' named entity 'SIGNIFICANT' named entity 'DENGUE' named entity 'PASSIVE IMMUNIZATION AGAINST' named entity 'ONCOLOGY' named entity 'RECENT' named entity 'HIGH' named entity 'NEGLECTED DISEASES' named entity 'ASSOCIATED WITH' named entity 'DOSE' named entity 'COULD BE' named entity 'ASSUMPTION' covid:arg/38c9ad4d6eb48945732f8519c795b39b4bdb0c93 named entity 'high-quality'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software